Agios Appoints Richa Poddar as Chief Commercial Officer
November 15 2021 - 4:01PM
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field
of cellular metabolism to treat genetically defined diseases, today
announced the appointment of Richa Poddar to the role of chief
commercial officer, effective Dec. 6, 2021. Ms. Poddar will replace
Darrin Miles, who currently serves as the company’s chief
commercial officer and has been with Agios since 2015. Mr. Miles
will depart the company to pursue a chief executive officer role at
a private biotechnology company.
“During her more than five-year tenure at Agios, Richa has
played a significant leadership role in shaping our oncology
portfolio and leading our oncology launch and marketing efforts,
making her the ideal person to take the reins as we prepare for the
launch of mitapivat in pyruvate kinase deficiency and continue to
advance our genetically defined disease commercial strategy,” said
Jackie Fouse, Ph.D., chief executive officer of Agios. “Richa has
masterfully contributed to Agios through roles of increasing
responsibility and complexity in marketing, portfolio leadership,
business development and corporate strategy, while fostering
creative and resourceful teams that drive results for patients and
exemplify the Agios culture. I look forward to more great things
from her as our new chief commercial officer.”
“I would also like to thank Darrin for his meaningful
contributions to Agios, including his foundational work building
and transforming our commercial capabilities, positioning us well
for our first genetically defined disease product launch, and his
leadership in commercial and program management roles supporting
the development, approval and commercialization of two precision
oncology medications,” continued Dr. Fouse. “Darrin has also played
a critical role in shaping our culture, encouraging team members to
challenge one another respectfully in order to achieve the best
results and ultimately deliver innovative medicines to patients. We
wish him the best of luck in his new role.”
Ms. Poddar joined Agios in 2016 and currently serves as senior
vice president, corporate strategy and business development. She
previously served as vice president, transition lead oncology
programs, head of the oncology portfolio and head of marketing. In
these capacities, Ms. Poddar played an important role in shaping
Agios’ oncology portfolio, providing strong cross-functional and
strategic program leadership, driving the preparation for Agios’
first two product launches and leading the transition of the
company’s oncology assets to Servier. Prior to joining Agios, she
worked in marketing at Clovis Oncology and spent eight years at
Genentech and F. Hoffman La-Roche where she held roles of
increasing responsibility, including marketing and market analytics
for various oncology products, including Herceptin®, Perjeta®,
Kadcyla®, Avastin® and Alecensa®. Prior to Genentech, she worked at
Amgen in the commercial analytics group. Ms. Poddar holds a B.E. in
computer engineering from Pune University and a Master’s in
biotechnology from Keck Graduate Institute in California.
About AgiosAgios is focused on discovering and
developing novel investigational medicines to treat genetically
defined diseases through scientific leadership in the field of
cellular metabolism. The company’s most advanced drug candidate is
a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that
is currently being evaluated for the treatment of three distinct
hemolytic anemias. In addition to its active late-stage clinical
pipeline, Agios has multiple novel, investigational therapies in
clinical and preclinical development. For more information, please
visit the company’s website at www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the expected benefits of Ms. Poddar’s appointment and
Agios’ strategic plans and focus. The words "expects,"
"anticipates," "believes," "intends," "estimates," "plans," "will,"
"outlook" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from Agios'
current expectations and beliefs. For example, the FDA’s acceptance
of Agios’s NDA for mitapivat does not represent evaluation of the
efficacy and safety of mitapivat, and is not a guarantee of
approval. Management's expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
important factors, including: risks associated with the regulatory
review process generally; the risk that the FDA may
determine that the data included in the NDA are insufficient for
approval and that the Company must conduct additional clinical
trials, or nonclinical or other studies, before mitapivat can be
approved; the risk that the results of previously conducted studies
involving mitapivat will not be repeated or observed in ongoing or
future studies or following commercial launch, if mitapivat is
approved; and risks associated with the Company’s dependence on
third parties with respect to regulatory matters for mitapivat.
These and other risks are described in greater detail under the
caption “Risk Factors” included in Agios’ public filings with
the Securities and Exchange Commission, or SEC. While the
list of factors presented here is considered representative, this
list should not be considered to be a complete statement of all
potential risks and uncertainties. Any forward-looking statements
contained in this communication are made only as of the date
hereof, and we undertake no obligation to update forward-looking
statements to reflect developments or information obtained after
the date hereof and disclaim any obligation to do so other than as
may be required by law.
Contacts
Investors: Holly Manning, 617-844-6630Senior
Director, Investor RelationsHolly.Manning@agios.com
Media: Jessi Rennekamp, 857-209-3286Director,
Corporate CommunicationsJessica.Rennekamp@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Sep 2023 to Sep 2024